Pursuant to ASX Listing Rule 17.1, Mesoblast Limited ACN 109 431...

Pursuant to ASX Listing Rule 17.1, Mesoblast Limited ACN 109 431 870 (ASX: MSB; NASDAQ:
MESO) (the Company) requests a trading halt in its securities effective immediately pending an
announcement by the Company in relation to the United States Food and Drug Administration’s
review of its Biologics License Application for RYONCIL® (remestemcel-L) in pediatric patients
with steroid-refractory acute graft versus host disease.
For the purposes of Listing Rule 17.1, the Company provides the following information:
(a) the trading halt is requested pending an announcement in relation to the matters
above;
(b) the Company requests that the trading halt continues until it makes an announcement
regarding the matters above which is expected to be on Monday, 5 October 2020; and
(c) the Company is not aware of any reason why the trading halt should not be granted or
of any other information necessary to inform the market about the trading halt.

I believe we are still waiting for an ann from FDA - hence Halt till then,